Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma

Journal of Gastrointestinal Cancer

Volumn 43, Issue 2, 2012, Pages 344-348

  Horgan, Anne M ^a   Dawson, Laura A ^a   Swaminat, Anand ^a   Knox, Jennifer J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Hepatocellular carcinoma; Radiation therapy; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; AMLODIPINE BESYLATE; INTERFERON; RAMIPRIL; RIBAVIRIN; SORAFENIB;

ADULT; ADVANCED CANCER; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASE REPORT; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; GINGIVA BLEEDING; HEPATITIS C; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; MALE; MOUTH ULCER; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMORADIOTHERAPY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES;

EID: 84863858253     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-010-9194-4     Document Type: Article

References (17)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90.
2. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099-109. (Pubitemid 39331023)
3. Hsu WC, Chan SC, Ting LL, Chung NN, Wang PM, Ying KS, et al. Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma. Jpn J Clin Oncol. 2006;36(2):93-9.
4. Ben-Josef E, Normolle D, Ensminger WD, Walker S, Tatro D, Ten Haken RK, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005;23(34):8739-47. (Pubitemid 46211519)
5. Mornex F, Girard N, Beziat C, Kubas A, Khodri M, Trepo C, et al. Feasibility and efficacy of high-dose three-dimensional - conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies - mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys. 2006;66(4):1152-8. (Pubitemid 44740208)
6. Seong J, Shim SJ, Lee IJ, Han KH, Chon CY, Ahn SH. Evaluation of the prognostic value of Okuda, Cancer of the Liver Italian Program, and Japan Integrated Staging systems for hepatocellular carcinoma patients undergoing radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67(4):1037-42.
7. Kim TH, Kim DY, Park JW, Kim YI, Kim SH, Park HS, et al. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol. 2006;29(6):568-75. (Pubitemid 44915292)
8. Liu MT, Li SH, Chu TC, Hsieh CY, Wang AY, Chang TH, et al. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. Jpn J Clin Oncol. 2004;34(9):532-9. (Pubitemid 43118049)
9. Park W, Lim DH, Paik SW, Koh KC, Choi MS, Park CK, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2005;61(4):1143-50. (Pubitemid 40340909)
10. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2008;26(4):657-64. (Pubitemid 351264363)
11. Fukumitsu N, Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Abei M, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009;74(3):831-6.
12. Ma BB, Bristow RG, Kim J, Siu LL. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol. 2003;21(14):2760-76. (Pubitemid 46613486)
13. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6(6):553-63. (Pubitemid 40017699)
14. Cao C, Albert JM, Geng L, Ivy PS, Sandler A, Johnson DH, et al. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res. 2006;66(23):11409-15. (Pubitemid 46009972)
15. Hsieh CH, Jeng KS, Lin CC, Chen CK, Liu CY, Lin CP, et al. Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. Clin Drug Investig. 2009;29(1):65-71.
16. Kasibhatla M, Steinberg P, Meyer J, Ernstoff MS, George DJ. Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2007;5(4):291-4. (Pubitemid 46867367)
17. Peters NA, Richel DJ, Verhoeff JJ, Stalpers LJ. Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol. 2008;26(14):2405-6.